2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1062

Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
Abstract Number: 1063

A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome
Abstract Number: 1064

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients
Abstract Number: 1065

A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score
Abstract Number: 1066

History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Abstract Number: 1067

History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Abstract Number: 1068

Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years
Abstract Number: 1069

The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis
Abstract Number: 1070

Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients
Abstract Number: 1071

Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Abstract Number: 1072

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Abstract Number: 1073

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Abstract Number: 1074

The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies
Abstract Number: 1075

CD40-Pathway Activation in Ectopic Lymphoid Structure (ELS)-Resident B Cells Contributes to Disease Pathology in Primary SjöGren’s Syndrome
Abstract Number: 1076

BAFF Receptor Antagonists Suppress Differentiation of B Cells in Vitro and Are Drug Candidates for Primary SjöGren’s Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].